



EMA
Domenico Scarlattilaan 6
1083 HS Amsterdam
The NETHERLANDS

Libourne, 27th November 2024

Subject: Withdrawal of Vectra 3D spot-on solution for dogs: New indication
EMEA/V/C/002555/VRA/0026/G

Dear Sirs,

For the withdrawal of a grouping application linked to an extension of the authorisation of a medicinal product already authorised

I would like to inform you that, at this point in time, Ceva Santé Animale has taken the decision to withdraw the application for a change to the marketing authorisation for Vectra 3D in the indication and in the pharmacodynamics properties.

This withdrawal is based on the following reason: the CVMP considers that the data provided do not allow the committee to conclude on a positive opinion.

We reserve the right to make further submissions at a future date in this or other therapeutic indications/target species, if applicable.

I agree for this letter to be published on the EMA website.

Yours faithfully,

